Hou Daorui, Yang Maoyi, Hu Zhipeng, Yang Liangjun
Department of Traditional Chinese Medicine Oncology, The First People's Hospital of Xiangtan City, Xiangtan, Hunan Province.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
Medicine (Baltimore). 2020 Jun 19;99(25):e20620. doi: 10.1097/MD.0000000000020620.
Chronic atrophic gastritis (CAG) is defined as an important precancerous disease with high risk of gastric cancer. Rebamipide is a mucosal protective agent widely used in the treatment of chronic gastritis. The aim of this systematic review is to assess the efficacy and safety of rebamipide for the treatment of patients with CAG.
We will perform a comprehensive retrieval in the following electronic databases: PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database (VIP), Chinese Biomedical Literature Service System (SinoMed) and other sources. Two trained researchers will select the qualified studies for data extraction and assess the quality and risk of bias, independently. Then the meta-analyses will be conducted by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Funnel plot analysis and Egger test will be used to assess the publication bias. Finally, the quality of evidence will be assessed by the GRADE system.
The results of our research will be published in a peer-reviewed journal.
The conclusion of our systematic review will provide evidence to judge whether rebamipide is an effective intervention for patient with CAG.
10.17605/OSF.IO/BKC3E.
慢性萎缩性胃炎（CAG）被定义为一种重要的胃癌前疾病，胃癌风险较高。瑞巴派特是一种广泛用于治疗慢性胃炎的黏膜保护剂。本系统评价的目的是评估瑞巴派特治疗CAG患者的疗效和安全性。
我们将在以下电子数据库中进行全面检索：PubMed、Embase、MEDLINE、Cochrane图书馆对照试验中央注册库、中国知网数据库、万方数据知识服务平台、维普中文科技期刊数据库、中国生物医学文献服务系统（SinoMed）及其他来源。两名经过培训的研究人员将独立选择合格的研究进行数据提取，并评估质量和偏倚风险。然后使用RevMan 5.2和Stata 14.0进行荟萃分析。将通过Cochrane X和I检验研究数据的异质性。进行敏感性分析以评估结果的稳定性。使用漏斗图分析和Egger检验评估发表偏倚。最后，将通过GRADE系统评估证据质量。
我们的研究结果将发表在同行评审期刊上。
我们系统评价的结论将为判断瑞巴派特是否是治疗CAG患者的有效干预措施提供证据。
10.17605/OSF.IO/BKC3E。
